Navigation Links
Future for radioembolisation in patients with advanced hepatocellular carcinoma
Date:4/24/2009

Copenhagen, Denmark, Friday 24 April: Radioembolisation with Yttrium-90 (Y-90) glass microspheres is a safe and effective treatment for patients with advanced HCC portal vein thrombosis, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.

According to the researchers, these findings create the foundation for a trial comparing and combining radioembolisation with multi-targeted kinase inhibitor, sorafenib. This would represent a new treatment option for sufferers of advanced HCC who currently have limited therapeutic choices.

HCC is a primary malignancy of the liver cells, generally leading to death within 6-20 months. It is currently one of the most common worldwide causes of cancer death. Locoregional treatment of HCC is considered the most effective palliative therapeutic approach. However, advanced tumour stages including portal vein thrombosis, diffuse multifocal liver infiltration and large tumour burden are obstacles for conventional local treatments. Due to the possibility of unselective application, radioembolisation with Yttrium-90 glass microspheres may allow effective local ablative therapy even in patients with intra-hepatic advanced HCC.

The aim of this open-label phase II study was to evaluate the safety and efficacy of radioembolisation in a European cohort of patients with locally advanced HCC and to assess the response rate according to different approved response criteria (WHO, RECIST and EASL).

Professor Guido Gerken, Head of Department of Hepatology and Gastroenterology, Essen University Hospital, Germany, who led the study, said: "In terms of a global strategy, we hope to achieve a major impact on the incidence of HCC through current vaccination strategies for HBV virus infection, screening and treatment for HCV infections, and from the reduction of alcoholic liver disease. However, because the latency period from hepatic damage to HCC development is very long, it may be many years until the incidence of HCC decreases as a result of these interventions. Previous therapeutic options have been limited to transplant or selective locoregional treatment but this exciting advance means new hope for HCC sufferers in the form of a novel treatment."

From November 2006 to August 2008, researchers in this study assessed 71 patients with advanced unresectable HCC portal vein thrombosis for inclusion in this prospective study. Y-90 microsphere radiotherapy was performed in a lobar fashion via the right or left hepatic artery. In bilobar disease, right and left liver lobes were treated with 4-6 weeks intervals in between. The mean radiation dose was 115 (23) Gy per treatment. Response rate was assessed according to (WHO, RECIST and EASL) criteria with sequential computed tomography scans till the last clinical visit or death. The safety of this technique was evaluated according to CTC toxicity criteria.

51/71 patients had a follow-up of at least six months. 52/71 patients had liver cirrhosis. 7.30% of the patients had portal vein thrombosis before therapy. Partial response rate was detected in 52%. With consideration of necrosis (EASL criteria) partial response was 80%. During the limited follow up, 2/70 patients died within the first month after therapy. 11/70 patients died within at least 6 months after therapy. Time to progression (TTP) was 6 months. One year survival rate was 72%. TTP and overall survival seem comparable to systemic therapy. The main adverse events were a transient fatigue-syndrome and lymphopenia. Five patients developed bilirubin elevation after therapy.


'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-078-761-90439
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. Health Care Policy Analyst Gives SALGBA Attendees a Glimpse of the Future
2. Consumers More Optimistic than Doctors Regarding Future of U.S. Health Care Reform
3. Scienceroll.com on The Future of Medicine: E-patients Will Shape Healthcare
4. Patient Room of the Future Speeds Healing
5. Hospital Build Asia Exhibition and Congress 2009 Sets the Stage for the Future of Healthcare
6. Marketing Technology Solutions Primed for Future Growth with Appointment of Rob Rebak as New CEO
7. Mayo study shows simple finger device may help predict future heart events, such as heart attack
8. Mayo Study Shows Simple Finger Device May Help Predict Future Heart Events, Such as Heart Attack
9. N.J.-Based Pest Control Company Using Tool of the Future to Kill Bed Bugs - Instant Freeze Technology is Completely Green
10. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
11. MTM Upgrades its Phone System to Ensure Leading edge Technology and Software Feature sets for Existing and Future Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Los Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... bariatric surgeons have noted that, less than 1% of United Kingdom residents who could ... the UK’s National Health Service (NHS) increases the number of bariatric procedures it offers ...
(Date:5/23/2016)... ... ... Researchers can find themselves in a state of semi-autopilot while pipetting, perhaps ... yield big benefits. Scientists might be surprised to learn how acquiring specific pipetting techniques ... the risk of contamination when working with eukaryotic cells. , Eppendorf is sponsoring a ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... objectification, according to Georgia State University researchers. , In a recent ... fifth, sixth and seventh grades shared their experiences with strained relationships, recurring ...
(Date:5/23/2016)... Austin, Texas (PRWEB) , ... May 23, 2016 ... ... May 23, the Texas Veterinary Medical Association (TVMA) reminds pet owners that intervening ... a serious emergency. Heatstroke occurs when a pet’s normal body mechanisms cannot keep ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
(Date:5/20/2016)... , May 20, 2016 ... veteran investors believe that the industry is not far ... and today ActiveWallSt.com featured the following four equities: Anacor ... (NASDAQ: ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ... INFI ). Sign up for your free ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
Breaking Medicine Technology: